Search

Search Results

• 

  Endothelin receptor antagonists: effects on extracellular matrix synthesis in primary cultures of skin fibroblasts from systemic sclerosis patients

  S. Soldano, P. Montagna, R. Brizzolara, C. Ferrone, A. Parodio, A. Sulli, B. Seriolo, B. Villaggio, M. Cutolo

  326-334

  11-12-2012

  Published: 11 December 2012

  1547

  PDF: 767
• 

  Efficacy of bosentan in the treatment of Raynaud’s phenomenon in patients with systemic sclerosis never treated with prostanoids

  S. Parisi, M. Bruzzone, C. Centanaro Di Vittorio, A. Laganà, C.L. Peroni, E. Fusaro

  286-291

  17-03-2014

  Published: 17 March 2014

  2415

  PDF: 1135
• 

  Bosentan and sildenafil: successful treatment in a sclerodermic patient with refractory ulcers

  E. Catarsi, M. Doveri, A. Tavoni

  79-81

  27-05-2013

  Published: 27 May 2013

  2987

  PDF: 813

• Two-years therapy with bosentan of pulmonary arterial hypertension related to connective tissue diseases

  H. Marotta, R. Montisci, F. Tiso, S. Pontarollo, M. Rizzo, F. Tona, S. Iliceto, F. Cozzi

  299-303

  Published:

  870

  PDF: 689

• Digital ulcers in a cohort of 333 scleroderma patients

  F. Tiso, M. Favaro, L. Ciprian, S. Cardarelli, M. Rizzo, M. Tonello, A. Ruffatti, F. Cozzi

  215-220

  Published:

  1040

  PDF: 792

• Treatment of digital ulcers in systemtic sclerosis with endothelin-1 receptor antagonist (bosentan)

  M.T. Riccardi, A. Chialà, F. Iannone, V. Grattagliano, M. Covelli, G. Lapadula

  135-139

  Published:

  1105

  PDF: 713